Pet Cancer Therapeutics Market Size
Pet Cancer Therapeutics Market size registered a valuation of over USD 369 billion in 2022 and is slated to exhibit more than 10% CAGR from 2023 to 2032 driven by the increasing willingness of pet parents to spend on their pets’ healthcare.
To get key market trends
Download Free Sample
The industry need is primarily fueled by a swelling number of pet cancer cases. The upsurge in canine & feline cancer is primed to drive the demand for effective pet cancer therapeutics to manage cancer conditions, further driving the business progress. According to the Merck Veterinary Manual, genetic factors can contribute to the development of cancer in companion animals. Additionally, positive efforts to improve canine therapies such as government funding have uplifted the industry outlook.
Furthermore, significant awareness among pet owners concerning pet diseases is expected to stimulate industry expansion. The growing understanding of pet cancer and commercially available treatments is boosting the demand for therapeutics and has broadened the use of these products. The prevalence of smartphones and the information available online have greatly increased pet owners' understanding of various illnesses.
Pet Cancer Therapeutics Market Report Attributes
| Report Attribute |
Details |
| Base Year |
2022 |
| Pet Cancer Therapeutics Market Size in 2022 |
USD 369 Million |
| Forecast Period |
2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR |
10% |
| 2032 Value Projection |
USD 1 Billion |
| Historical Data for |
2018 to 2022 |
| No. of Pages |
140 |
| Tables, Charts & Figures |
241 |
| Segments covered |
Therapy, Route of Administration, Species, Application, and Region |
| Growth Drivers |
- Rising prevalence of pet cancer
- Rising awareness among pet owners regarding pet diseases
- Increasing pet care expenditure
- Technological advancements in pet cancer therapeutics including cancer immunotherapy
- High medical unmet needs and strong potential
|
| Pitfalls & Challenges |
- Side-effects associated with pet cancer therapeutics
- Lack of veterinary oncologists
|
What are the growth opportunities in this market?
Download Free Sample
Side effects associated with pet cancer therapies may restrain industry progression
Adverse effects from pet cancer therapies are a major factor restraining pet cancer therapeutics market share. Similar to humans, chemotherapy in dogs and cats causes low white blood cell count, vomiting, dehydration, diarrhea, lethargy, and bladder irritation. In September 2022, the FDA warned pet owners regarding a potential threat to dogs with skin cancer cream fluorouracil or 5-FU due to consistent deaths of dogs. Nonetheless, recent breakthroughs in cancer treatment for pets are expected to be beneficial for the market landscape.
Pet Cancer Therapeutics Market Analysis
Learn more about the key segments shaping this market
Download Free Sample
Pet cancer therapeutics market from the chemotherapy segment is set to be worth more than USD 628 million by 2032. The most common treatment of lymphoma cancer treatment, particularly for companion animals, is chemotherapy. According to a study by the Flint Animal Cancer Center, canine lymphoma accounting for almost 24% of all new cases of canine cancer in 2019, was one of the most frequently diagnosed diseases in dogs.
In terms of application, the pet cancer therapeutics market from mast cell cancer is set to witness over 8.5% CAGR over 2023-2032. Increased incidences of respective malignancy affecting the gastrointestinal system, bone marrow, liver, and spleen, especially in dogs, is escalating the need for cancer therapies in this tumor type. A 2022 research study found that salivary miR-21 has the potential in detecting the MCT-affected salivary gland in dogs playing the role of a biomarker for the treatment of mast cell tumors.
Pet cancer therapeutics market from the oral route of administration segment is projected to reach a valuation of more than USD 359 million by 2032. Notable developments in oral medicines due to their clinical benefits, including the ease & comfort of home therapy and fewer clinic visits, are bolstering segment expansion. In a recent instance, in May 2022, the FDA granted conditional approval to Laverdia-CA1 or Verdinexor tablets, the first chemotherapy pills for dogs with lymphoma. These pills can induce apoptosis and enrich the antiproliferation of cancer cells for chemotherapeutic agents.
In 2022, the biggest market for pet cancer treatments was for dogs, reaching over $352 million. This is because more dogs are getting cancer, especially cats. And it's not just because there are more petsinbreeding and non-purebred dogs are more likely to get tumors and lymphoma. Also, dogs are living longer these days because of better medicine and care. But this means they're also more likely to get cancer as they get older. So, the rise in the number of older dogs is another reason for the increase in cancer cases.
Learn more about the key segments shaping this market
Download Free Sample
The market for cancer treatments for pets in North America is expected to grow to over $774 million by 2032. This growth is being driven by several factors, includingIncreased spending on veterinary carePet owners are spending more money on their pets' health, which is creating a demand for new and better cancer treatments. Rising number of pet cancer cases Cancer is one of the leading causes of death in pets, and the number of cases is increasing. Government support for pet cancer research Governments are providing funding for research into new pet cancer treatments, which is helping to drive innovation in this area. One example of this support is a recent $1 million investment by Petco Love and Blue Buffalo. This investment is funding research at 12 university veterinary partners, which is expected to lead to new and improved treatments for pet cancer.
Pet Cancer Therapeutics Market Share
Some of the key players in the pet cancer therapeutics market are
- Zoetis Inc.
- Merial Inc.
- Elanco Animal Health
- Anivive Lifesciences
- Qbiotics
- AB Science
- NovaVive
- ELIAS Animal Health
These firms are engaging in new product R&D programs to achieve a competitive edge in the business. For instance, in June 2022, biopharmaceutical firm, Boehringer Ingelheim, along with CarthroniX, a developer of small molecule-based therapies for aging-related and degenerative diseases, announced a research partnership to create small molecule therapeutics in canine oncology. This innovation is likely to aid the company in expanding the Animal Health division of Boehringer Ingelheim and present an innovative approach to canine cancer treatment.
Impact of the COVID-19 pandemic
The pet cancer therapeutics industry witnessed slightly slow growth during the COVID-19 pandemic as a result of disruptions in the healthcare system for animals. As per the Global Animal Health Association 2020 report, pet owners in a study reported delayed or missed care for pets in many countries which impeded veterinary services. Meanwhile, pet owners embraced pet pharmaceuticals to ensure the health of their animals, which supported the demand for pet medicines to protect animals from chronic illnesses. Seamless services from numerous animal welfare organizations benefitted the animal healthcare system and further boosted pet care therapeutics.
The pet cancer therapeutics market report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2018 to 2032 for the following segments
Click here to Buy Section of this Report
By Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Combination Therapy
By Route of Administration,
By Species
By Application
- Lymphoma
- Mast Cell Cancer
- Melanoma
- Mammary and Squamous Cell Cancer
- Others
The above information is provided for the following regions and countries
- North America
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Sweden
- Switzerland
- The Netherlands
- Austria
- Poland
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Philippines
- New Zealand
- Latin America
